Medical/Pharmaceuticals
Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) onOctober 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO...
2025-10-24 16:40
1019
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanci...
2025-10-24 07:30
2424
METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate MTS-004 has...
2025-10-23 21:21
1638
HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
* Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. * Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Hanch...
2025-10-23 19:00
2074
International Youth Explore the Wisdom of Traditional Chinese Medicine Zhangshu National Pharma Fair Opens a New Chapter in Cultural Experience
ZHANGSHU, China, Oct. 23, 2025 /PRNewswire/ -- A report from Jiangxi International Communication Center (JXICC): "Without Zhangshu, medicines are incomplete; without Zhangshu, medicines lack efficacy." OnOctober 16, 2025, Jiangxi's Zhangshu Qihuang Town was bustling with crowds as the 56th Nation...
2025-10-23 14:46
1464
MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring
SÃO PAULO, Oct. 22, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing essential tools and technologies to drive innovation in the life sciences, has entered into a strategic partnership with Eva Holding Group, a Brazilian group operating in genomics applied to hum...
2025-10-23 11:30
1364
Charming Medical Limited Announces Closing of Initial Public Offering
HONG KONG, Oct. 22, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), aHong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the closing of its initial public offering (the "Offering") of 1,600,000 Class A ordin...
2025-10-23 00:51
2124
SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging
LAS VEGAS, Oct. 22, 2025 /PRNewswire/ -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company fromTaiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which w...
2025-10-23 00:00
1447
The Blood Center in New Orleans modernizes platelet processing with FDA-cleared automation from Terumo Blood and Cell Technologies
— Second U.S. site to deploy the Reveos™ system, boosting platelet supply and reducing waste LAKEWOOD, Colo., Oct. 22, 2025 /PRNewswire/ -- To help address platelet shortages and streamline blood center operations, The Blood Center inNew Orleans has become the second U.S. blood center to impleme...
2025-10-22 22:39
1464
Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that theBlood published the latest result...
2025-10-22 19:39
1450
LISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient
SEOUL, South Korea, Oct. 22, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This approval marks...
2025-10-22 14:28
1232
Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology
TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku,Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku,Tokyo). T...
2025-10-22 14:00
997
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
* The only company from pharmaceutical industry selected for inclusion in the Index * Also included in HSI ESG Index and Hang Seng ESG 50 Index * Green CRDMO solution provider with outstanding sustainability performance HONG KONG, Oct. 21, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a lea...
2025-10-22 08:30
2654
Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq
HONG KONG, Oct. 21, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), aHong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the pricing of its initial public offering (the "Offering") of 1,600,000 Class A ordin...
2025-10-21 23:00
1947
HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO). Titled"E...
2025-10-21 19:00
1918
Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy
TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological artificial intelligence (AI) system. DeepMind re...
2025-10-21 10:49
1320
SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and co...
2025-10-21 09:20
1381
WellsCare Partners with Celltrion Canada to Bring Advanced Wearable Pain Relief Tech to North America
SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- WellsCare, a South Korean medical technology startup, announced that onOctober 9, it signed a Memorandum of Understanding (MOU) with Celltrion Canada, a subsidiary of the global biopharmaceutical leader Celltrion. This strategic partnership is set...
2025-10-20 21:00
1643
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of the fastest-growing fields in emerging medicine....
2025-10-20 19:43
1088
HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stag...
2025-10-20 19:00
1595
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09